Circulating microparticles and central blood pressure according to antihypertensive strategy

Autor(es)

Nayara D. Massunaga ^[1] ; Carolina N. França ; Henrique T. Bianco ^[3] ; Carlos E.S. Ferreira ; Juliana T. Kato ^[5] ; Rui M.S. Póvoa ^[6] ; Antonio M. Figueiredo Neto ^[7] ; Maria Cristina O. Izar ^[8] ; Francisco Antonio Helfenstein Fonseca ^[9]

Afiliação do(s) autor(es)

^[1] Universidade Federal de Sao Paulo (UNIFESP). Departamento de Medicina - Brasil

^[3] Universidade Federal de Sao Paulo (UNIFESP). Departamento de Medicina - Brasil

^[5] Universidade Federal de Sao Paulo (UNIFESP). Departamento de Medicina - Brasil

^[6] Universidade Federal de Sao Paulo (UNIFESP). Departamento de Medicina - Brasil

^[7] Universidade Sao Paulo. Instituto Nacional de Ciencia e Tecnologia de Fluidos Complexos - Brasil

^[8] Universidade Federal de Sao Paulo (UNIFESP). Departamento de Medicina - Brasil

^[9] Universidade Federal de Sao Paulo (UNIFESP). Departamento de Medicina - Brasil

• Tipo de documento: Artigo Científico
• Fonte: Clinics; v. 74, 2019-11-11.

Resumo

OBJECTIVES: This prospective, randomized, open-label study aimed to compare the effects of antihypertensive treatment based on amlodipine or hydrochlorothiazide on the circulating microparticles and central blood pressure values of hypertensive patients. METHODS: The effects of treatments on circulating microparticles were assessed during monotherapy and after the consecutive addition of valsartan and rosuvastatin followed by the withdrawal of rosuvastatin. Each treatment period lasted for 30 days. Central blood pressure and pulse wave velocity were measured at the end of each period. Endothelial, monocyte, and platelet circulating microparticles were determined by flow cytometry. Central blood pressure values and pulse wave velocity were recorded at the end of each treatment period. RESULTS: No differences in brachial blood pressure were observed between the treatment groups throughout the study. Although similar central blood pressure values were observed during monotherapy, lower systolic and diastolic central blood pressure values and early and late blood pressure peaks were observed in the amlodipine arm after the addition of valsartan alone or combined with rosuvastatin. Hydrochlorothiazide-based therapy was associated with a lower number of endothelial microparticles throughout the study, whereas a higher number of platelet microparticles was observed after rosuvastatin withdrawal in the amlodipine arm. CONCLUSIONS: Despite similar brachial blood pressure values between groups throughout the study, exposure to amlodipine was associated with lower central blood pressure values after combination with valsartan, indicating a beneficial interaction. Differences between circulating microparticles were modest and were mainly influenced by rosuvastatin withdrawal in the amlodipine arm. (AU)

• Processo FAPESP: 08/57685-7 - Instituto Nacional de Ciência e Tecnologia de Fluídos Complexos
• Beneficiário: Antonio Martins Figueiredo Neto
• Modalidade de apoio: Auxílio à Pesquisa - Temático